Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 907-915

  Singh, Onkar ^a   Saxena, Saurabh ^a   Mishra, Sanjeev ^a   Khuroo, Arshad ^a   Monif, Tausif ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Bioequivalence; Ganciclovir; LC MS MS; Solid phase extraction; Valganciclovir

Indexed keywords

ACICLOVIR; GANCICLOVIR; METHANOL; TRIFLUOROACETIC ACID; VALACICLOVIR; VALGANCICLOVIR; WATER;

ARTICLE; BIOEQUIVALENCE; CATION EXCHANGE; DRUG DETERMINATION; DRUG ISOLATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; PLASMA; POSITIVE ION ELECTROSPRAY; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ACYCLOVIR; CALIBRATION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; GANCICLOVIR; HUMANS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TIME FACTORS; VALINE;

EID: 79958779471     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.003     Document Type: Article

References (14)

1. Abu-Nader Patel R. Current management strategies for the management and treatment of cytomegalovirus infection in solid organ transplant recipient. BioDrugs 2000, 134:159-175.
2. Sherris medical microbiology 2004, 556. McGraw Hill, 566-9. 4th ed. K.J. Ryan, C.G. Ray (Eds.).
3. Drew W.Lawrence, Ives David, Lalezari Jacob P., Crumpacker Clyde, Follansbee Stephen E., Spector Stephen A., et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. New Engl J Med 1995, 333:615-620.
4. Perrottet N., Beguin A., Meylan P., Pascual M., Manuel O., Buclin T., et al. J Chrm B 2007, 8552:420-429.
5. DoganTopal B., Uslu B., Ozkan S.A. Development and validation of an RP-HPLC method for determination of valganciclovir in human serum and tablets. Chromatographia September 2007, 66(Supplement 1):97-101.
6. Chu F., Kiang C.H., Sung M.L., Huang B., Reeve R.L., Tarnowski T. J Pharm Biomed Anal Nov 1999, 21(3):657-667. 1.
7. Masahiko T., Shuuji H., Masahiko K., Megumi F., Nobufumi O., Masaaki K. Determination of anti-virus drug, ganciclovir, in human serum by HPLC with precolumn fluorescence derivatization using phenylglyoxal. Anal Sci 2001, 17(7):811.
8. Satoshi K., Yoh T., Mitsuru S., Tsuyoshi S., Hiroyuki F., Satoru T., et al. Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. J Chromatogr B November 25 2002, 780(2):289-294.
9. Anders A., Christin N.H., Leon R. Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. J Pharm Biomed Anal February 19 2007, 43(3):1039-1044.
10. Mercus B., Hugh W., Christian K., George W., Christoph R. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. Pediatr Infect Dis J 2004, 23:263.
11. Hong R.X., Xue N.L., Wei L.C., Gang Y.L., Nan N.C., Chen Y. A sensitive assay for simultaneous determination of plasma concentrations of valganciclovir and its active metabolite ganciclovir by LC/MS/MS. J Chromatogr B 2007, 848:329.
12. Guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CBM) May 2001.
13. Viswathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., et al. AAPS J 2007, 9(1):E30.
14. FDA guidance for industry: bioavailability studies for orally administered drug-products - general considerations. US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER) 2000.